GHIF II is now live and actively fundraising to ensure continued support to Raydiant.
Global Health Impact Fund (GHIF) is a clinician-founded healthcare venture capital firm based in Silicon Valley, with a proven track record of identifying and supporting transformative healthtech startups.
Our inaugural fund, GHIF I — launched in 2019 and fully subscribed at $10M — has achieved two successful exits from 10 investments:
Somnoware, acquired by ResMed in 2023 (3.3x return)
UBERDOC, acquired by ROV Investment Partners in 2025
We’re now raising GHIF II, targeting $50M, with a first close at $25M. Notably, 40% of GHIF I Limited Partners have already reinvested — a strong vote of confidence in our strategy and performance.
A key focus of GHIF II is Raydiant Oximetry, a clinical-stage medical device company advancing maternal and fetal health. GHIF has been a committed investor since Raydiant’s seed round in 2019, supporting its FDA approval, major grants from the Gates Foundation and NIH, and a recent joint development initiative with GE HealthCare.
GHIF II plans to participate in Raydiant’s Series B round, with an anticipated exit in 2026 offering strong return potential.